Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy

Table 4 The incidence of drug-associated adverse events in experimental and control participants, n (%)

Characteristic	Experimental group (n = 60)	Control group (n = 50)	P value
Hypertension	3 (5.00)	0 (0.00)	0.054
I	2 (3.30)	0 (0.00)
II	1 (1.70)	0 (0.00)
Proteinuria	4 (6.70)	5 (10.00)	0.526
I	2 (3.35)	3 (6.00)
II	2 (3.35)	2 (4.00)
Gastrointestinal perforation	0 (0.00)	0 (0.00)	-
I	0 (0.00)	0 (0.00)
II	0 (0.00)	0 (0.00)
Bleeding	1 (1.70)	0 (0.00)	0.269
I	1 (1.70)	0 (0.00)
II	0 (0.00)	0 (0.00)
Arterial thrombosis	0 (0.00)	0 (0.00)	-
I	0 (0.00)	0 (0.00)
II	0 (0.00)	0 (0.00)
Thrombocytopenia	7 (11.70)	5 (10.00)	0.780
I	3 (5.00)	3 (6.00)
II	4 (6.70)	2 (4.00)
Pneumonia, nephritis, hepatitis, and endocrine disorders	0 (0.00)	0 (0.00)	-
I	0 (0.00)	0 (0.00)
II	0 (0.00)	0 (0.00)
Diarrhea and enteritis	3 (5.00)	2 (4.00)	0.801
I	2 (3.30)	2 (4.00)
II	1 (1.70)	0 (0.00)
Number of cases	18	12	0.525
I	10	8
II	8	4